All peptides
Growth hormoneModerate

Ipamorelin

NNC 26-0161

The most selective of the growth-hormone secretagogues, valued because it lifts GH without meaningfully raising cortisol or prolactin.

How it works

Acts as a ghrelin receptor (GHS-R1a) agonist on the pituitary, triggering a clean GH pulse. Its selectivity avoids the appetite and cortisol effects seen with older secretagogues like GHRP-6.

Structure: Pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2)

Reported benefits

  • Clean GH pulse without hunger spikes
  • Better sleep quality and recovery
  • Mild fat-loss and body-composition support

Practical considerations

  • Weakest GH release of the GHRPs — usually stacked with CJC-1295
  • Effects build over weeks, not days
  • Dose ceiling: more than ~300 mcg per pulse gives diminishing returns

Side effects and risks

  • Mild headache
  • Injection-site redness
  • Light-headedness shortly after dosing

Ipamorelin dosing overview

200–300 mcg per dose, often 100–300 mcg before bed

Reported Ipamorelin dosing ranges by context
ContextAmountFrequencyRoute
Standard reported dose200–300 mcg1–3× dailySubcutaneous
Before bed only100–300 mcgOnce nightlySubcutaneous

This describes doses reported in published literature and community protocols. It is not a recommendation, and it is not a substitute for clinical supervision.

Ipamorelin FAQ

What is ipamorelin?

A pentapeptide ghrelin-receptor (GHS-R1a) agonist that triggers a pulse of growth-hormone release from the pituitary. It is described as selective because, unlike older secretagogues, it has little effect on cortisol or prolactin at typical doses.

Does ipamorelin make you hungry?

Much less than ghrelin itself or GHRP-6. It hits the same receptor but produces weaker appetite signalling, which is one reason it is preferred in community protocols.

Why is it dosed on an empty stomach?

Elevated blood glucose and insulin blunt growth-hormone release, so protocols space doses away from meals to avoid dampening the pulse.

Is ipamorelin FDA-approved?

No. It reached early clinical study and was discontinued. It is not approved, is restricted for US compounding, and is banned in sport.

Research references

  • Raun et al., 1998 — Ipamorelin, the first selective growth hormone secretagogue